Use of an extract from a culture of thermophilic strain <i>Staphylococcus aureus</i>in the complex therapy of a patient with atopic dermatitis: a clinical case

Atopic dermatitis refers to type 2 inflammatory disease. It is associated with genetic predisposition to allergies, immune dysregulation, skin barrier dysfunction and characterized by chronic relapsing course. Activation of T2 inflammation in atopic dermatitis is a complex interaction between innate and adaptive immune mechanisms, epidermal cells, nervous system, and microbial factors, leads to the development of local and systemic inflammation, characterized by activation and proliferation of type 2 T-helper cells, group 2 innate lymphoid cells, and the involvement of pro-inflammatory type 2 cytokines. Understanding these processes opens opportunities for targeted biological therapy and selective immunosuppressive therapy aimed at blocking key cytokines of T2 inflammation. Agents with non-specific action affecting immune dysregulation in allergic diseases are also being introduced into clinical practice. They are presented by specific natural or recombinant regulatory peptides and proteins. One of such drugs is a pharmaceutical product with an extract from thermophilic strain Staphylococcus aureus culture as an active substance. The article presents a clinical case of an adult patient with severe atopic dermatitis complicated by bacterial infection with positive response to use a drug, based on an extract from thermophilic strain Staphylococcus aureus culture.